Baricitinib: Baricitinib, an orally administered, selective, reversible JAK1/2 inhibitor.
Study summary
This is a prospective, open-label phase 1b/2 clinical trial to explore the safety and efficacy profiles of baricitinib in patients with thrombopoietin-receptor-agonist-refractory persistent thrombocytopenia after allogeneic hematopoietic stem cell transplantation.
Eligibility
Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
* Aged 18-70 years;
* Underwent allo-HSCT;
* Meet the diagnostic criteria for delayed platelet engraftment (DPE) or secondary failure of platelet recovery (SFPR);
* Have platelet counts consistently \<20 ×10\^9/L or transfusion-dependent within 14 days prior to enrollment;
* Have received adequate corticosteroid and TPO-RA therapy for persistent thrombocytopenia for no less than 4 weeks, with treatment failure or intolerance;
* Complete donor chimerism.
Exclusion Criteria:
* Relapse of hematologic malignancy or MRD positivity;
* Active infection;
* Active graft-versus-host disease;
* Thrombotic microangiopathy;
* Primary graft failure or poor graft function;
* Presence of other factors that may lead to secondary thrombocytopenia at the time of PT diagnosis;
* History of systemic herpes zoster infection within 12 weeks prior to enrollment screening;
* Acute or chronic infection with HBV, HCV, or HIV;
* Evidence of active tuberculosis, or history of active tuberculosis without documented standard anti-tuberculosis treatment, or close contact with active tuberculosis without documented standard tuberculosis prophylaxis;
* Receipt of a live vaccine within 12 weeks prior to enrollment screening, or planned receipt of a live vaccine during the study period;
* Clinically significant thromboembolic event within 24 weeks prior to enrollment screening, or current use of anticoagulant medications deemed by the investigator to carry an uncontrollable risk;
* Estimated glomerular filtration rate \<50 mL/min/1.73 m\^2;
* Severe pre-existing or current conditions involving the cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, nervous, or neuropsychiatric systems, or other severe or unstable illnesses or laboratory abnormalities that will make the study drug unacceptable for the patient or can interfere study data;
* Participation in another clinical trial within 30 days prior to enrollment.
Primary outcome measure(s)
Adverse events in the Ib part — 24 weeks The incidence and severity of adverse events are assessed using the criteria of CTCAE 5.0.
Overall response rate (ORR) for the IIa part — 12 weeks The proportion of patients achieving an overall response (OR), defined as a platelet count ≥20×10\^9/L maintained for more than 7 days without transfusion support. Platelet counts obtained within 4 weeks after rescue therapy were not included in the efficacy assessment.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.